OE?A?INUeEEE IAOEIAEE A?A??I?*IEE OeAIO?

EIAAEAIEI

Oai?ea Aiaoie??aia

OAeE 618.177-089.888.11(048.8)

OeEOIAAIAOE*IA OA II?OIOOIEOe?IIAEUeIA OA?AEOA?ENOEEA IIOeEO?A ETHAeEIE

O CA’ssCEO C ?O CAIE?AeIAIIssI IN VITRO (EE?I?EI-AENIA?EIAIOAEUeIA
AeINE?AeAEAIIss)

03.00.15 – aaiaoeea

Aaoi?aoa?ao aeena?oaoe??

ia caeiaoooy a/aiiai nooiaiy

eaiaeeaeaoa a?ieia?/ieo iaoe

EE?A – 1999

4

Aeena?oaoe??th ? ?oeiien

?iaioa aeeiiaia a Oe?a?inueeiio iaoeiaiio oeaio?? iaaee/ii? aaiaoeee IIC
? IAI Oe?a?ie

Iaoeiaee ea??aiee: eaiaeeaeao a?ieia?/ieo iaoe,
noa?oee iaoeiaee ni?a?ia?oiee

Noaoaiiae/ Aaiia Aieiaeeie??aia

Oe?a?inueeee iaoeiaee oeaio? iaaee/ii? aaiaoeee IIC ? IAI Oe?a?ie,
caa?aeoth/a eaai?aoi???th aaiaoeee ?aiiueiai ?icaeoeo ethaeeie

Io?oe?ei? iiiiaioe: aeieoi? a?ieia?/ieo iaoe,
i?ioani?

Aeai?aeia Na?a?e A?eoi?iae/

Ee?anueeee iaoe?iiaeueiee oi?aa?neoao ?i. Oa?ana Oaa/aiea, caa?aeoth/ee
eaoaae?ith

caaaeueii? oa iieaeoey?ii? aaiaoeee

eaiaeeaeao a?ieia?/ieo iaoe,

Ca?iaa-Ethaeiiaa Oaoyia Aaeoa?ae?aia

Ee?anueea iaaee/ia aeaaeai?y i?neyaeeieiiii? ina?oe ?i. I.E. Ooieea IIC
Oe?a?ie, i?ia?aeiee iaoeiaee ni?a?ia?oiee

I?ia?aeia onoaiiaa: ?inoeooo iieaeoey?ii? a?ieia?? ?
aaiaoeee IAI Oe?a?ie, a?aeae?e aaiaoeee ethaeeie, i. Ee?a

Caoeno a?aeaoaeaoueny “28” o?aaiy 1999 ?. i 1000 aiaeei? ia can?aeaii?
niaoe?ae?ciaaiii? a/aiii? ?aaee Ae26.604.01 Oe?a?inueeiai iaoeiaiai
a?a??i?/iiai oeaio?o, 253660 i. Ee?a-94, aoe. Iiioae?aiea,50

C aeena?oaoe??th iiaeia iciaeiieoenue o a?ae?ioaoe? Oe?a?inueeiai
iaoeiaiai

a??i?/iiai oeaio?o, i. Ee?a, aoe. Iiioae?aiea,50

Aaoi?aoa?ao ?ic?neaiee “16” ea?oiy

A/aiee nae?aoa?

niaoe?ae?ciaaii? a/aiii? ?aaee _____________________ Naeaciueia A.TH.

CAAAEUeIA OA?AEOA?ENOEEA ?IAIOE

Aeooaeuei?noue oaie. Iaoiae caie?aeiaiiy in vitro (in vitro
fertilization, IVF) – iaeia c aeiiii?aeieo ?ai?iaeoeoeaieo oaoiieia?e –
oe?iei ai?iaaaeaeo?oueny a iaaee/io i?aeoeeo aaaaoueio e?a?i na?oo ye
iaoiae e?eoaaiiy aacie?aeaey. Nooue oeueiai iaoiaeo iieyaa? a io?eiaii?
aeic??eeo iioeeo?a ethaeeie i?ney ai?iiiaeueii? noeioeyoe??
noia?iaoeyoe??, caie?aeiaii? ?o iica i?aai?ciii oa ia?aiin? aia??ii?a a
iaoeo ae?iee, aea a?aeaoaa?oueny ?o ?iieaioaoe?y ? iiaeaeueoee ?icaeoie.

Aeaiia?ao?/ia oa ai?aeai?ieia?/ia neooaoe?y a Oe?a?i? a inoaii? ?iee
oa?aeoa?eco?oueny aeaiiioeyoe??th ? aenieei ??aiai aacie?aeaey (a?ey 20%
iiae?oaei?o ia?), ui ia? oaiaeaioe?th aei c?inoaiiy (A?euaiei, 1997).
Oiio iaaoaa? aaeeei? aaae e?eoaaiiy aacie?aeaey, cie?aia ca aeiiiiiaith
iiaeo ?ai?iaeoeoeaieo oaoiieia?e, ye? aeicaieythoue ae??ooaaoe cia/io
e?euee?noue i?iaeai, ui iia’ycai? ye c ae?ii/ei, oae ? c /ieia?/ei
aacie?aeaeyi. Naia iia? ?ai?iaeoeoeai? oaoiieia?? iiaeooue noaoe iaeiei
?c ae??aeo cania?a caa?aaeaiiy aaiioiiaeo Oe?a?ie a oiiaao aeieia?/ii?
e?ece, iineeaii? *i?iiaeeuenueeith eaoano?ioith.

A oaia??oi?e /an a Oe?a?i? ?nio? n?i eaai?aoi??e, ui aeei?enoiaothoue
iaoiae IVF aeey e?eoaaiiy ??cieo oi?i aacie?aeaey. Iacaaaeath/e ia oa,
ui a?o/eciyieie a/aieie oa ee?i?oeenoaie aeei?enoiao?oueny aeina?ae
i?ia?aeieo eaai?aoi??e na?oo, aoaeoeai?noue iaoiaeo ana ua eeoa?oueny
aeineoue iecueeith. C e?oa?aoo?e a?aeiii, ui o cia/ii? /anoeie iioeeo?a,
ye? aoee io?eiai? a noeioeueiaaieo oeeeeao, aeyaeythoueny o?iiiniii?
aiiiae?? (Angell et al, 1986; Plachot et al, 1989; Noaoaiiae/, Aa?eeye,
1994). Iiaeeeai, iaaaea/? e?eoaaiiy aacie?aeaey ca aeiiiiiaith iaoiaeo
IVF iaoiiaeai? iaaieie ii?oiooieoe?iiaeueieie oa?aeoa?enoeeaie iioeeo?a,
a oaeiae o?iiiniiieie aiiiae?yie, ui aeieeathoue i?ae /an aaiaoiaaiaco,
caie?aeiaiiy ? ?aiiueiai aia??iiaeueiiai ?icaeoeo. Aeai? i?i o?iiiniii?
aiiiae?? a aaiaoao oa aei?iieaioaoe?eieo aia??iiao ethaeeie
ciaoiaeyoueny ia noaae?? iaeiie/aiiy.

I?e/eie oa iaoai?cie oaeeo ii?ooaiue eeoathoueny iaei aea/aieie.
I?eionea?oueny, ui ?yae a?ieia?/ieo oa ee?i?/ieo oaeoi??a,
iaeaieiai?oeie c yeeo ? a?e ae?iee, iieacaiiy aei IVF i?ioeaaeo? oa
ai?iiiaeueia noeioeyoe?y noia?iaoeyoe??, iiaeooue aieeaaoe ia
e?euee?ni?, ii?oiooieoe?iiaeuei? oa oeeoiaaiaoe/i? oa?aeoa?enoeee
io?eiaieo iioeeo?a ?, a oe?eiio, ia aoaeoeai?noue i?ioeaaeo?e
caie?aeiaiiy in vitro (Galan et al, 1992; Winston et al, 1993).
Ii?oiooieoe?iiaeueia oa oeeoiaaiaoe/ia aeine?aeaeaiiy iioeeo?a ethaeeie,
ui aeei?enoiaothoueny a IVF i?ia?aiao, ? aeeeth/ii aeooaeueiei ?
aeicaiey? aeyaeoe ii?ooaiiy a yeoeaee?oeiao ae?iie oa anoaiiaeoe aieea
??cieo /eiiee?a ia oa?aeoa?enoeee io?eiaieo iioeeo?a.

Ca’ycie ?iaioe c iaoeiaeie ieaiaie, oaiaie. Aeena?oaoe?eia ?iaioa
aeeiiaia a ?aieao aea?aeaaii? iaoeiai-aeine?aeii? i?ia?aie Caoeno
aaiioiiaeo ianaeaiiy Oe?a?ie, oeo? 01.01.

Iaoith ?iaioe aoei aeine?aeaeaiiy ii?oiooieoe?iiaeueieo oa
oeeoiaaiaoe/ieo oa?aeoa?enoee iioeeo?a ethaeeie oa aieeao ia ieo aeayeeo
ee?i?/ieo oa a?ieia?/ieo oaeoi??a (a?eo ae?iee, ai?iiiaeueii?
noeioeyoe?? oa iieacaiue aei IVF).

Caaea/? aeine?aeaeaiiy:

1. Anoaiiaeoe iniiai? oeie oa ??aaiue oeeoieia?/ieo ? o?iiiniiieo
aiiiae?e, ye? cono??/athoueny a iacaie?aeiaieo iioeeoao ethaeeie.

2. Aeyaeoe aca?iica’ycie i?ae e?euee?nieie ? ii?oieia?/ieie
oa?aeoa?enoeeaie io?eiaieo iioeeo?a oa ??aiai ?o caie?aeiaiiy ? ianoaiiy
aaa?oiino?.

3. Aea/eoe aieea a?eo ae?iee, ai?iiiaeueii? noeioeyoe?? oa iieacaiue
aei canoinoaaiiy IVF ia oa?aeoa?enoeee iioeeo?a.

4. Aeine?aeeoe aieea a?eo, aeic oa noai ai?iiiaeueii? noeioeyoe??
noia?iaoeyoe?? ia ii?oieia?/i? oa oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a
ieoae e?i?? NAA oa i?iaanoe ii??aiyeueiee aiae?c c ?acoeueoaoaie
aeine?aeaeaiiy iioeeo?a ethaeeie.

Iaoeiaa iiaecia iaea?aeaieo ?acoeueoao?a.

1. Aia?oa i?iaaaeaii eiiieaenio ioe?ieo e?euee?nieo,
ii?oiooieoe?iiaeueieo oa oeeoiaaiaoe/ieo oa?aeoa?enoee iioeeo?a ethaeeie
a caeaaeiino? a?ae ??cieo a?ieia?/ieo oa ee?i?/ieo oaeoi??a.

2. Aia?oa anoaiiaeaii aca?iica’ycie i?ae ii?oieia?/ieie
oa?aeoa?enoeeaie iioeeo?a, a?aenioeii aiiiaeueiiai ?o caie?aeiaiiy oa
??aiai caie?aeiaiiy iioeeo?a ? ianoaiiy aaa?oiino?.

3. I?iaaaeaii ii??aiyiiy aieeao a?eo, aeic oa noai ai?iiiaeueii?
noeioeyoe?? noia?iaoeyoe?? ia ii?oieia?/i? ? oeeoiaaiaoe/i?
oa?aeoa?enoeee iacaie?aeiaieo iioeeo?a ethaeeie oa iioeeo?a ieo?.

I?aeoe/ia cia/aiiy aeine?aeaeaiiy. Io?eiai? ?acoeueoaoe iiaeooue aooe
aeei?enoai? a ee?i?eao, ui canoiniaothoue iaoiae IVF.

1. Aeine?aeaeaiiy e?euee?nieo ? ii?oieia?/ieo oa?aeoa?enoee iioeeo?a,
io?eiaieo i?ney ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe??, aeicaiey?
i?iaiicoaaoe ??aaiue ?o caie?aeiaiiy oa ianoaiiy aaa?oiino?.

2. Aeai? i?i aieea a?ieia?/ieo ? ee?i?/ieo oaeoi??a ia oa?aeoa?enoeee
iioeeo?a aeicaieyoue ioe?ieoe aeey ie?aii? ae?iee ?iia??i?noue
caie?aeiaiiy oa ianoaiiy aaa?oiino? a caeaaeiino? a?ae ?? a?eo oa
iieacaiue aei IVF.

3. ?acoeueoaoe aeine?aeaeaiiy /anoioe o?iiiniiieo aiiiae?e a
iacaie?aeiaieo iioeeoao aeey ie?aii? ae?iee iiaeooue aooe i?aenoaaith
aeey ?aeiiaiaeaoe?? aeei?enoaiiy yeoeaee?oei aeiii?a.

4. Anoaiiaeaiiy ni?eueieo caeiiii??iinoae i?e aeine?aeaeaii? aieeao
a?eo oa noai ai?iiiaeueii? noeioeyoe?? ia iioeeoe ethaeeie oa ieo? iiaea
i?aeoaa?aeeoe iioeiaeuei?noue aeei?enoaiiy ieoae e?i?? NAA ye
iiaeaeueii? nenoaie aeey aea/aiiy aieeao ??cieo oaeoi??a ia
aoaeoeai?noue IVF i?ioeaaeo?.

Iniaenoee aianie caeiaoaa/a. Aeena?oaioii iniaenoi i?iaaaeaii
i?eaeeoo?aa aeine?aeaeaiiy oa o?enaoe?y iacaie?aeiaieo iioeeo?a,
io?eiaieo a ee?i?oe? Isida IVF ; oeeoiaaiaoe/ia aeine?aeaeaiiy oa
ea??ioeioaaiiy oeeoiaaiaoe/ieo i?aia?ao?a; aenia?eiaioe ii
aeine?aeaeaiith aieeao a?eo oa ai?iiiaeueii? noeioeyoe?? ia iioeeoe
ieoae e?i?? NAA; ?ic?iaeaii aieaoo aeaieo i?i iaoe??ioie, iioeeoe yeeo
aeine?aeaeoaaeenue a oe?e ?iaio?. Aaoi?ii naiino?eii aeeiiaii
noaoenoe/iee aiae?c io?eiaieo ?acoeueoao?a oa i?aeaioiaaii oaeno
aeena?oaoe??.

Aaoi? aeneiaeth? ue?o iiaeyeo aee?aeoi?o Oe?a?inueeiai iaoeiaiai oeaio?o
iaaee/ii? aaiaoeee Aa?eeyeo ?.?. ca iino?eio i?aeo?eieo oa aeiiiiiao
i?ae /an aeeiiaiiy ?iaioe, ni?a?ia?oieeai ee?i?ee Isida IVF oa
?inoeoooo ?ai?iaeoeoeaii? iaaeeoeeie (??I) ca iaaeaiiy iaoa??aeo oa
aeaieo i?i iaoe??ioie, i.i.n. Aanaiei I.I. ca i?eaeeoo?ao ioe?ieo oa
o?enaoe?th iacaie?aeiaieo iioeeo?a, io?eiaieo a ??I, no.i.n. Eae?c? I.A.
ca i?iaaaeaiiy aacaeoii?? naioe?a ieoae e?i?? NAA.

Ai?iaaoe?y ?acoeueoao?a aeena?oaoe??. Iniiai? iieiaeaiiy ?iaioe
aeiiia?aeaeenue ia iaoeiaiio neiiic?oi? Aanieiaeea: aniiiiaaoaeueiua
?ai?iaeoeoeaiua oaoiieiaee (Ee?a, 1997), ia iaoeiai-i?aeoe/i?e
eiioa?aioe?? Aoaeoeai?noue i?aiaoaeueii? ae?aaiinoeee o i?io?eaeoeoe?
a?iaeaeaii? oa niaaeeiai? iaoieia?? (Oaoeuee, 1998), ia i?aeia?iaeiiio
eiia?an? “The First World Congress of A PART (The International
Assosiation of Privat Assisted Reproductive Technology Clinics and
Laboratories)” (Venice, 1999).

Ioae?eaoe??. Ca oaiith aeena?oaoe?? aoei iioae?eiaaii 9 ae?oeiaaieo
?ia?o, a oiio /ene? 6 noaooae.

Ianya oa no?oeoo?a ?iaioe. Aeena?oaoe?eia ?iaioa aeeeaaeaia ia 126
noi??ieao iaoeiiieniiai oaenoo, neeaaea?oueny ?c anooio, iaeyaeo
e?oa?aoo?e, ?acoeueoao?a aeanieo aeine?aeaeaiue, iaaiai?aiiy,
caeeth/aiiy, aeniiae?a, ia?ae?eo aeei?enoaieo aeaea?ae. Oaeno
aeena?oaoe?? ?ethno?iaaiee 23 oaaeeoeyie oa 16 ?enoieaie. Ia?ae?e
aeei?enoaieo aeaea?ae i?noeoue 216 iaca.

CI?NO ?IAIOE

Iaoa??aee oa iaoiaee

I?ae /an aeeiiaiiy ?iaioe aeine?aeaeoaaeeny iioeeoe, io?eiai? a?ae 214
ae?iie, ye? i?ioiaeeee eo?n e?eoaaiiy aacie?aeaey iaoiaeii caie?aeiaiiy
in vitro o ee?i?oe? “?s?da IVF” oa a ?inoeooo? ?ai?iaeoeoeaii?
iaaeeoeeie (??I), i.Ee?a.

AE?iee aoee iiae?eai? ia a?oie a caeaaeiino? a?ae a?eo (3 a?oie: ? –
aei 26 ?ie?a; ?? – 26-34 ?ie?a; ??? –iiiaae 34 ?iee), oeio aacie?aeaey
(4 a?oie: ? – c o?oaii-ia?eoiiaaeueiei aacie?aeaeyi; ?? – c aiaeie?eiiei
aacie?aeaeyi; ??? – c ?ae?iiaoe/iei aacie?aeaeyi; ?V – c aacie?aeaeyi,
i?e/eiith yeiai aoa /ieia?/ee oaeoi?), noaie ai?iiiaeueii? noeioeyoe??
(3 a?oie: ? – aac aeei?enoaiiy aaii?no?a aiiaaeio?ii?i ??e?c?ia ai?iiio
(Ai?Aa), ?? – Ai?Aa+; ??? – Ai?Aa+const. noaia), ??aiy caie?aeiaiiy (4
a?oie: ? – c ??aiai caie?aeiaiiy 0-25%; ?? – c ??aiai caie?aeiaiiy
26-50%; ??? – c ??aiai caie?aeiaiiy 51-75%).

Aieea a?eo oa noai ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe?? ia
oa?aeoa?enoeee iioeeo?a aea/aee ia iiaeaeuei?e nenoai? – ieoao e?i??
NAA.

Aeey aea/aiiy aieeao a?eo ia noai iioeeo?a aoei aeine?aeaeaii o?e a?oie
ieoae (ii10 oaa?ei a eiaei?e): “iieiaeoiai”, “na?aaeiueiai” oa
“noa?oiai” a?eo. Aeey aeine?aeaeaiiy aieeao ??cieo aeic aaaaeaieo
ai?iii?a aoee aeae?eai? 4 a?oie ieoae a?eii 8-12 oeaei?a (ii10 oaa?ei a
eiaei?e): ? a?oia (eiio?ieue) – iioeeoe io?eioaaee o i?e?iaeiiio oeeee?;
?? a?oia – oaa?eiai aaiaeeee ii 5 II aiiaaeio?ii?i?a; ??? a?oia –
oaa?eiai aaiaeeee ii 10 II aiiaaeio?ii?i?a; ?V a?oia – oaa?eiai aaiaeeee
ii 15 II aiiaaeio?ii?i?a. Aeey aea/aiiy aieeao ??cieo noai ai?iiiaeueii?
noeioeyoe?? ia oa?aeoa?enoeee iioeeo?a aoei aeine?aeaeaii o?e a?oie
ieoae a?eii 8-12 oeaei?a: ? a?oia (eiio?ieue) – iioeeoe io?eioaaee o
i?e?iaeiiio oeeee?; ?? a?oia– noeioeyoe?th i?iaiaeeee ca noaiith
aiiaaeio?ii?i ne?iaaoee aea?aaeo eiaee + oi??ii?/iee aiiaaeio?ii?i
ethaeeie (OAE); ??? a?oia– noeioeyoe?th i?iaiaeeee ca noaiith
iaiiiaocaeueiee aiiaaeio?ii?i ethaeeie + OAE.

Iioeeoe ae?iie io?eioaaee a ee?i?eao oeyoii o?ainaaa?iaeueii? ioieoe??
oa ani??aoe?? i?aiaoeyoi?ieo oie?eoe?a i?ae eiio?ieai oeueo?aniiia?ao??
i?ney ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe??. A?aoiaoaaee oaeee
iieaciee, ye e?euee?noue io?eiaieo iioeeo?a a ?ic?aooieo ia iaeio
ae?ieo, a oaeiae ?acoeueoaoe ?o i?eaeeoo?aiai ii?oieia?/iiai aiae?co:
e?euee?noue aeic??eeo/iaaeic??eeo iioeeo?a oa yeoeaee?oei c iciaeaie
aeaaaia?aoe??. Iacaie?aeiai? iioeeoe aeinoaaeyee o eaai?aoi??th aeey
i?eaeeoo?aiai aeine?aeaeaiiy oa o?enaoe??.

Iaoeyoi?i? iioeeoe ieoae iaea?aeoaaee oeyoii ai?iiiaeueii? noeioeyoe??
noia?iaoeyoe??, yeo i?iaiaeeee ca noaiaea?oiith iaoiaeeeith (Aogan et
al, 1986).

Iacaie?aeiai? iioeeoe ethaeeie oa io?eiai? iioeeoe ieoae i?aeaeaaaee
i?eaeeoo?a?e ii?oieia?/i?e ioe?ioe? (a?aoiaoaaee noai oeeoiieacie:
nooi?iue a?aioeueiaaiino?, u?euei?noue; ia?ea?oae?iiaiai i?inoi?o;
iayai?noue 1-ai iiey?iiai o?eueoey; o?aaiaioaoe??; iciae aeaaaia?aoe??),
ca ?acoeueoaoaie yei? aeae?eyee iioeeoe caaeia?eueii? oa iecueei?
yeino?.

O?enaoe?y iioeeo?a i?iaiaeeeany ca iaoiaeaie Almeida, 1993; Micamo et
al, 1983; Wramsby, 1985.

Aeey ia’?eoea?caoe?? oa i?enei?aiiy o?iiiniiiiai aiae?co aeei?enoiaoaaee
aaoiiaoeciaaio iioeei-aeaeo?iiio nenoaio “Iaoaneai-2” (ni?eueiiai
ae?iaieoeoaa o??ie “Iio?ii” oa Oe?a?inueeiai iaoeiaiai oeaio?o iaaee/ii?
aaiaoeee, i. Ee?a).

On? noaoenoe/i? ?ic?aooiee aeeiioaaee ca aeiiiiiaith niaoe?aeueieo
i?ia?ai ia i?e?ieaeueeoeyoi?? “Aeaeo?ii?ea IE 61”.

?acoeueoaoe aeine?aeaeaiiy oa ?o iaaiai?aiiy

Aeine?aeaeaiiy ooieoe?iiaeueieo oa oeeoiaaiaoe/ieo oa?aeoa?enoee
iioeeo?a ethaeeie

I?iaaaeaia aeine?aeaeaiiy aeaei ciiao ii??aiyoe ooieoe?iiaeuei? oa
oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a ethaeeie, io?eiaieo a ??cieo
oeaio?ao e?eoaaiiy aacie?aeaey: ee?i?oe? ”Isida IVF” oa ?inoeooo?
?ai?iaeoeoeaii? iaaeeoeeie (??I). A eiaei?e c ee?i?e iioeeoe aoee
io?eiai? a?ae 107 ae?iie a?eii a?ae 19 aei 42 ?ie?a, na?aaei?e a?e 30,6
4,5 ?ie?a (??I) oa a?eii a?ae 19 aei 44 ?ie?a, na?aaei?e a?e 31,2 5,1
?ie?a (”Isida IVF”). Na?aaeiy e?euee?noue iioeeo?a ia ae?ieo noaiiaeea
10,6 0,7, ?ica?a 1-33 (??I) oa 10,5 0,6, ?ica?a 3-28 (”Isida IVF”).
E?euee?noue caie?aeiaieo oa iacaie?aeiaieo iioeeo?a ia ae?ieo a iaio
oeaio?ao e?eoaaiiy aacie?aeaey aeinoia??ii ia a?ae??ciyeanue (5,7 0,5
oa 4,8 0,4 a?aeiia?aeii, “Isida IVF” ? 5,1 0,7 oa 5,5 0,7
a?aeiia?aeii, ??I), ui aeicaiey? aiai?eoe i?i iaeaea ?aeaioe/i?
ooieoe?iiaeuei? oa?aeoa?enoeee iioeeo?a, io?eiaieo a ??cieo ee?i?eao.
Io?eiai? iaie ?acoeueoaoe ciaoiaeyoueny a iaaeao iieaciee?a aiaeia?/ieo
aeine?aeaeaiue, i?iaaaeaieo a ??cieo IVF oeaio?ao. ??aaiue caie?aeiaiiy
a iaio aeiaaeeao noaiiaeoue ~50%, ui ocaiaeaeo?oueny c aeaieie ?ioeo
aeine?aeiee?a (Winston et al, 1993) oa aaaaea?oueny ii?iaeueiei
caaaeueiii?eeiyoei ??aiai caie?aeiaiiy i?e IVF i?ioeaaeo?ao.

Oeeoiaaiaoe/iiio aiae?co i?aeeyaaee 288 iacaie?aeiaieo iioeeo?a c ??I oa
204 – c ee?i?ee ”Isida IVF”. ?acoeueoaoe aeine?aeaeaiiy iieacaee, ui
iaeaea on? oa?aeoa?enoeee ?o ciaoiaeyoueny a iaaeao ?acoeueoao?a
aiaeia?/ieo aeine?aeaeaiue. Oae, iniiaia e?euee?noue yeoeaee?oei
ciaoiaeeeany ia noaae?? I ?? iaeico (61,1% ??I oa 57,8% ”Isida IVF”), ui
ocaiaeaeo?oueny c aeaieie, iaaaaeaieie a ?ioeo ?iaioao (Noaoaiiae/ e
ae?., 1995). ??aaiue aeeiei?ae??, aiiiae??, yea aeieea? aiane?aeie
ii?ooaiiy aeae?eaiiy iiey?iiai o?eueoey i?ae /an ia?oiai iiae?eo
aeic??aaiiy, noaiiaea 5,3% (??I) oa 6,9% (”Isida IVF”), ui aeeae/a aei
ieaeiuei? iaae? oeueiai iieacieea (Angell et al, 1986). Iie?iei?ae?y
(e?euee?noue o?iiinii i?eaeecii aei??aithaaea oao?aiei?aeiiio iaai?o
o?iiinii) cono??/aeany a 1,0% (??I) oa 0,5% (”Isida IVF”) yeoeaee?oei.
??aaiue aeaaaia?aoe?? o?iiiniiiiai iaoa??aeo– 20,1% (??I) oa 24,0%
(”Isida IVF). Iacia/ia e?euee?noue iioeeo?a – 1,4% (??I) oa 0,5% (”Isida
IVF”) aoee iaaeic??eeie ? ciaoiaeeeeny ia noaae?? oaeioace ? iaeico.
Aaaaea?oueny, ui yeoeaee?oeie c ia?aae/aniith eiiaeainaoe??th o?iiinii
(IEO) nia?iaoici?ae?a oaeiae iaaeic??e?, oiio ui oey aiiiae?y aeieea?
/a?ac iaaeeeoeiao i?enooi?noue oaeoi?o i?iiioe?? iaeico (Tejada et al,
1992). A iaoiio aeine?aeaeaii? a 12,7% (??I) oa 13,7% (”Isida IVF”)
iioeeo?a, ii?yae c iaoaoaciith ieanoeieith o?iiinii iioeeoo
niinoa??aaeany IEO nia?iaoici?aea. Oiio iiaeia aaaaeaoe, ui caaaeueia
e?euee?noue iaaeic??eeo iioeeo?a noaiiaeoue 13,4%. A oie aea /an
iioeeoe, a yeeo niinoa??aa?oueny IEO nia?iaoici?ae?a, iaeaaeaoue aei
aiiiaeueii caie?aeiaieo yeoeaee?oei (Edwards et al, 1984), ye ?
iie?nia?iii caie?aeiai? iioeeoe (Woll, 1988), /anoioa yeeo neeaaea?, ca
iaoeie aeaieie, 3,5% (??I) oa 1,5% (”Isida IVF”). Oeeoiaaiaoe/iee
aiae?c oaeiae aeyaea 7,6% a ??I oa 5,9% o ee?i?oe? ”Isida
IVF”aia??ii?a, ye? coieieeeny ia ?aii?o noaae?yo ae?iaeaiiy. Oaeei
/eiii, a 21,9% iioeeo?a, ye? aaaaeaeeny iacaie?aeiaieie, a?aeaoeiny
caie?aeiaiiy, i?e/iio a 6,9% oea aoei ii?iaeueia caie?aeiaiiy, aea /a?ac
iaanoaiiaeai? i?e/eie ae?iaeaiiy aia??ii?a i?eieieeiny ia ii/aoeiaeo
noaae?yo, a o 15% – a?aeaoeiny aiiiaeueia caie?aeiaiiy. ??aaiue
niiioaiii? ia?oaiiaaiaoe/ii? aeoeaaoe?? a iaoiio aeine?aeaeaii? noaiiaea
3,8% (??I) oa 2,9% (”Isida IVF”). Oe? oeeo?e aeecuee? aei ?acoeueoao?a
Wojcik et al, 1995 (2,7%). C oaeeo iioeeo?a iiaeooue ?icaeaaoeny
aaiei?aei? aia??iie, /anoeia yeeo aeia i?ae /an ae?iaeaiiy, ia?aae aai
a?ae?aco i?ney ?iieaioaoe??, a aeaye? – ia ii/aoeo i?aaiiaaiaco (De
Sutter, 1992).

Caaaeueia ii??aiyiiy ?acoeueoao?a oeeoiaaiaoe/iiai aiae?co iioeeo?a,
io?eiaieo a aeaio oeaio?ao e?eoaaiiy aacie?aeaey, ia aeyaeei
aeinoia??ieo a?aei?iiinoae o oeeoiaaiaoe/ieo oa?aeoa?enoeeao
iacaie?aeiaieo iioeeo?a. Oiio ie aaaaea?ii, ui iiaeia aiai?eoe i?i
caaaeueio noeoii?noue iioeeo?a, ui aoee io?eiai? i?ae /an IVF
i?ioeaaeo? o ee?i?eao i?noa Ee?aa. E??i oiai, io?eiai? iaie aeai? i?i
ooieoe?iiaeuei? oa oeeoiaaiaoe/i? oa?aeoa?enoeee iacaie?aeiaieo iioeeo?a
? oe?eeii ii??aiyiieie c ?acoeueoaoaie ?ioeo aeine?aeiee?a. Aea, a oie
aea /an, ?niothoue nooo?a? ?ica?aeiino? aeaieo a iaaeao eiaeii? a?oie
iioeeo?a. Oiio iiaeia aiai?eoe, ui ia ?iciiae?e iacaie?aeiaieo iioeeo?a
ca ?o oa?aeoa?enoeeaie iiaeooue aieeaaoe ??ci? oaeoi?e (ee?i?/i?,
a?ieia?/i? oa ?i.), iiaa i?i ye? i?aea ieae/a.

Aeine?aeaeaiiy ii?oieia?/ieo oa?aeoa?enoee iioeeo?a ethaeeie

Iaie aoei anoaiiaeaii, ui a?eueo?noue iacaie?aeiaieo iioeeo?a ethaeeie
ia noaae?? iaoaoace ?? (I??) iaeico iaee caaeia?euei? ii?oieia?/i?
oa?aeoa?enoeee (oaae. 1). Aieea ii?oieia?/ieo oa?aeoa?enoee ia ??aaiue
caie?aeiaiiy aoa iienaiee ?yaeii aeine?aeiee?a (Zenzes et al, 1997, Zhen
et al, 1992). A iaoiio aeine?aeaeaii? aoei iieacaii, ui ii?oieia?/i?
oa?aeoa?enoeee iia’ycai? c ??aiai caie?aeiaiiy, ye ii?iaeueiiai, oae ?
aiiiaeueiiai, oa ia aieeaathoue ia ??aaiue niiioaiii? aeoeaaoe?? (oaae.
2).

Oaae. 1.

Ca’ycie i?ae ii?oieia?/ieie oa oeeoiaaiaoe/ieie oa?aeoa?enoeeaie
iioeeo?a

Oeeoiaaiaoe/i? oa?ae.

Ii?oie. oa?ae.Oaeioaca ?Iaoaoaca
??Aeeiei?-aei?Iie?iei-?aei?Aeaaaia-?aoe?yIioeeoe caaeia?eueii? yeino?, %
50,025,0 78,82,6*53,89,850,025,050,55,1Iioeeoe iecueei? yeino?, %
50,025,0 21,22,646,29,850,025,0 49,55,1*?0,05 I?e ii??aiyii? iioeeo?a
ii?iaeueii? oa iecueei? yeino?

Oaae. 2.

Ca’ycie i?ae ii?oieia?/ieie oa?aeoa?enoeeaie iioeeo?a oa ??aiai
caie?aeiaiiy ? ia?oaiiaaiaoe/ii? aeoeaaoe??

Iieaciee

Ii?oie.oa?aeoa?.Aia??iieIEOIie?nia?i?yIa?oaiiaaiacIioeeoe caaeia?eueii?
yeino?, % 76,57,3*86,44,8*76,911,7*58,811,9Iioeeoe iecueei? yeino?, %
23,57,313,74,823,111,741,211,9*?0,05 I?e ii??aiyii? iioeeo?a ii?iaeueii?
oa iecueei? yeino?

O?iiiniiiee aiae?c iacaie?aeiaieo iioeeo?a ethaeeie

O?iiiniiiee aiae?c iacaie?aeiaieo iioeeo?a ethaeeie ia noaae?? I??
iaeico iieacaa, ui eeoa 47,0% yeoeaee?oei iaee ii?iaeueiee iaa??
o?iiinii (?en. 1). Iniiaiith o?iiiniiiith aiiiae??th a iacaie?aeiaieo
iioeeoao ethaeeie aoea aiaoiei?ae?y, i?e/iio /anoioa a?iiaaiei?ae??
neeaaeaea 39,0%, a a?ia?aaiei?ae?? – 11,0%. A aeine?aeaeoaaieo
iioeeoao aiaoiei?ae?y /ano?oa aoea iia’ycaia c iaaeeeoeii aai
iaaeinoa/ath oe?eeo o?iiinii (78,0%), i?ae o?iiaoeae (18,0%). Aoei
oaeiae c’yniaaii, ui iae/ano?oa aiaoiei?ae?y aeieea? aiane?aeie
ia?icoiaeaeaiiy o?iiinii a?oi A oa G, a /anoioa ia?icoiaeaeaiiy o?iiinii
a?oie A aeinoia??ii ieae/a i/?eoaaii?. *anoioa iie?iei?ae??
a iioeeoao, ui aoee a?ae?a?ai? aeey o?iiiniiiiai aiae?co, neeaaeaea
2,0%. No?oeoo?i? aiiiae?? aoee aeyaeai? a 1,0% yeoeaee?oei.

Aieea a?ieia?/ieo oa ee?i?/ieo oaeoi??a ia oa?aeoa?enoeee iioeeo?a

Aeine?aeaeaiiy aieeao a?eo ae?iee ia ii?oiooieoe?iiaeuei? oa
oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a. A iao?e ?iaio? ie aea/aee ye
ii?oiooieoe?iiaeuei?, oae ? oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a
ethaeeie. Anoaiiaeaii iinooiiaa cieaeaiiy e?eueeino? iioeeo?a ia ae?ieo
c a?eii (13,31,1 i?ioe 10,60,7 oa 8,80,6 a?, ?? ? ??? a?oiao
a?aeiia?aeii, ? < 0,05 ), ca?eueoaiiy e?eueeino? iaaeic??eeo iioeeo?a o ae?iie noa?oiai a?eo (17,91,6% o ??? a?oi? i?ioe 13,31,0% oa 12,81,4% a ?? ? ? a?oiao a?aeiia?aeii, p < 0,05). E?euee?noue aeeiei?aeieo iioeeo?a o ae?iie ??cieo a?eiaeo a?oi a iaoiio aeine?aeaeaii? aoea iaeaea iaci?iiith (4,91,9%; 5,51,5%; 5,32,0% o ?, ?? ? ??? a?oiao a?aeiia?aeii), e??i oiai, anoia?a/ aeaiei Yie, 1996, iaie aoei iieacaii aeinoia??ia ca?eueoaiiy e?eueeino? iie?nia?iii caie?aeiaieo iioeeo?a c c?inoaiiyi a?eo ae?iee (0% o ? a?oi? i?ioe 2,10,9% oa 6,12,1% o ?? oa ??? a?oiao, ?<0,05) . Na?aae iacaie?aeiaieo yeoeaee?oei o ae?iie noa?oiai a?eo aeinoia??ii ca?eueooaaeany e?euee?noue iioeeo?a iecueei? yeino? (35,14,2% o ??? a?oi? oa 32,43,0% o ?? a?oi? i?ioe 15,43,3% a ? a?oi?, p<0,05). Ie anoaiiaeee i?iii?oe?eia cieaeaiiy ??aiy ianoaiiy aaa?oiino? c a?eii iaoe??ioie, aea ??cieoey i?ae oeeie iieacieeaie a ??cieo a?eiaeo a?oiao ia aoea aeinoia??iith (18,65,9%; 15,63,5%; 12,94,3% a ?, ?? oa ??? a?oiao a?aeiia?aeii). Ia aeaeue, a?eueo?noue aeine?aeaeaiue ii?oieia?/ieo oa oeeoiaaiaoe/ieo oa?aeoa?enoee i?iaiaeeeiny ia iioeeoao ethaeeie, ye? caeeoeeeny iacaie?aeiaieie, oiio aeieeaei ieoaiiy, /e iiaeia aeno?aiiethaaoe aeyaeai? caeiiii??iino? ia anth noeoii?noue io?eiaieo iioeeo?a. Aeey ae??oaiiy oe??? i?iaeaie i?iaiaeeeeny aenia?eiaioe ia oaa?eiao, iae/ano?oa ia ieoao. A?eueo?noue aeine?aeiee?a i?eae?eyee oaaao ci?iai o o?iiiniiiiio noai? iioeeo?a. A iaei?e c ?ia?o iienaii cieaeaiiy ??aiy niiioaiii? iaoeyoe?? o ieoae a?eii iiiaae 300 aei?a (Hartshorne, 1994). ??aaiue aiaoiei?ae?? oaeiae c?inoaa c a?eii ieo? (Brovk, 1984). A iaoiio aeine?aeaeaii? aea/aany aieea a?eo ye ia ii?oieia?/i?, oae ? ia oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a ieo?. Aoei iieacaii cia/ia iia??oaiiy cacia/aieo oa?aeoa?enoee c c?inoaiiyi a?eo oaa?eie. E??i oiai, aoei i?iaaaeaii ii??aiyiiy io?eiaieo ?acoeueoao?a aeey iioeeo?a ethaeeie oa ieo? (oaae. 3). Iacia/i? ?ica?aeiino? o aieea? a?eo ia aeaye? oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a ieo? oa ethaeeie iiaeia iiynieoe oei, ui a yeoeaee?oeiao ethaeeie, ye? caeeoeeeny iacaie?aeiaieie, a?aeaoaathoueny aeaui ?io? o?iiiniii? ci?ie. Aea caaaeueia iia??oaiiy oa?aeoa?enoee, ui aeine?aeaeoaaeeny, i?eoaiaiia iioeeoai ye ethaeeie, oae ? ieo?. Oiio iiaeia aaaaeaoe, ui ca?eueoaiiy a?eo ae?iee – oea oaeoi?, yeee iaaaoeaii aieeaa? ia ii?oieia?/i? oa oeeoiaaiaoe/i? oa?aeoa?enoeee an??? noeoiiino? io?eiaieo iioeeo?a, a, oaeei /eiii, ? ia ??aaiue caie?aeiaiino? oa ianoaiiy aaa?oiino?; ia oe?e i?aenoaa? eiai iiaeia aaaaeaoe oaeoi?ii, yeee e?i?oo? oni?oia i?iaaaeaiiy IVF i?ia?ai. Aea/aiiy aieeao ??cieo oi?i aacie?aeaey ia oa?aeoa?enoeee io?eiaieo iioeeo?a Aei iaoiai /ano ia ?nio? iaeiinoaeii? aeoiee i?i aieea iieacaiue aei IVF ia ii?oiooieoe?iiaeuei? oa oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a. O oai?eo c ?ae?iiaoe/iith oi?iith aacie?aeaey /ano?oa niinoa??aaeeny ia?oaiiaaiaoe/ii aeoeaiaai? iioeeoe, ii??aiyii c ae?ieaie c o?oaii-ia?eoiiaaeueiei aacie?aeaeyi (Plachot, 1988). Iao? aeine?aeaeaiiy oaeiae aeyaeee oaeo caeiiii??i?noue, aea ??cieoey ia aoea aeinoia??iith (6,73,2% o ae?iie c ?ae?iiaoe/iith oi?iith aacie?aeaey i?ioe 3,21,2% c o?oaii- ia?eoiiaaeueiei aacie?aeaeyi). Oaae. 3. Ii??aiyiiy ii?oieia?/ieo oa oeeoiaaiaoe/ieo oa?aeoa?enoee iioeeo?a ethaeeie oa ieo? a caeaaeiino? a?ae a?eo, (M+m) A?oia1 iieiaeoee a?e2 na?aaei?e a?e3 noa?oee a?eIieacieeethaeeiaieoaethaeeiaieoaethaeeiaieoaE?euee?noue iioeeo?a ia iniao, n13,31,121,22,210,60,7*20,62,38,80,6*9,82,7*Iacaie?aeiai? ioee-oe ii?iaeueii? yeino?, %84,63,398,90,767,63,0*87,62,5*64,94,2*69,85,0*Iacaie?aeiai? iioeeoe iecueei? yeino?, %15,43,31,10,732,43,0*12,42,5*35,14,230,25,0*Iaaeic??e? iioeeoe, %––2,10,9*1,81,3–10,74,1*Iioeeoe ia noaae?? I??, aaiei?aeiee iaa?? o?iiinii, %66,74,288,92,757,13,267,94,4*58,04,360,76,6*Aeaaaia?aoe?y o?iiinii, %16,33,36,72,221,02,625,04,4*22,14,517,95,1*Ia?oaiiaaiac, %2,41,4–4,21,31,81,33,11,57,13,4**p < 0,05 – aeinoia??i?noue a?aei?iiinoae a ii??aiyii? c ia?oith a?oiith. Ca aeaieie aeayeeo aeine?aeiee?a, aoaeoeai?noue IVF i?ioeaaeo? iaeaeua o aeiaaeeo o?oaii-ia?eoiiaaeueiiai aacie?aeaey (Ramesh, 1996) ? iaeiaioa – o aeiaaeeo /ieia?/iai aacie?aeaey (Plachot, 1988). O aeiaaeeo c ?ae?iiaoe/iith oi?iith aacie?aeaey ??aaiue caie?aeiaiiy ieae/ee, i?ae o iaoe??io?a c o?oaiei oaeoi?ii, a oie aea /an ??aaiue ?iieaioaoe?? oa ianoaiiy aaa?oiino? a oeeo aeiaaeeao iaeiaeiaee (Mahadevan, 1983). Ca iaoeie aeaieie, iaeiaioa e?euee?noue iaaeic??eeo iioeeo?a niinoa??aaeany o iaoe??ioie c o?oaii-ia?eoiiaaeueiei aacie?aeaeyi (9,10,9% i?ioe 18,91,6% c aiaeie?eiiei aacie?aeaeyi oa 19,92,1% o aeiaaeeo, eiee i?e/eiith aacie?aeaey aoa /ieia?/ee oaeoi?, p<0,05). E?euee?noue aeic??eeo yeoeaee?oei aoea iaeieae/ith o ?ac? aiaeie?eiiiai aacie?aeaey (74,01,8%) oa o aeiaaeeo, eiee i?e/eiith aacie?aeaey aoa /ieia?/ee oaeoi? (73,52,3% i?ioe 82,41,2% c o?oaii-ia?eoiiaaeueiei oa 79,42,2% c ?ae?iiaoe/iei aacie?aeaeyi, p<0,05). Iaeaeuee ??aaiue caie?aeiaiiy niinoa??aaany o ae?iie c ?ae?iiaoe/iith oi?iith aacie?aeaey (70,52,7% i?ioe 50,92,2% c aiaeie?eiiei aacie?aeaeyi, 49,22,0% c o?oaii-ia?eoiiaaeueiei aacie?aeaeyi oa 43,32,6% o aeiaaeeo, eiee i?e/eiith aacie?aeaey aoa /ieia?/ee oaeoi?, p<0,05), oe? aeai? noia?a/aoue ?acoeueoaoai, iaaaaeaiei aeua (Mahadevan, 1983). Aeinoia??ii a?eueoa e?euee?noue iioeeo?a ii?iaeueii? yeino? niinoa??aaeanue o iaoe??io?a, i?e/eiith aacie?aeaey o yeeo aoa /ieia?/ee oaeoi? (79,04,5%, ?<0,05). E??i oiai, o oeeo iaoe??io?a aoa iaeieae/ee ??aaiue aiiiaeueiiai caie?aeiaiiy (IEO – 4,02,3% oa iie?nia?i?? – 0%, p<0,05), ui aeia?a ocaiaeaeo?oueny c ?acoeueoaoaie ?ioeo aeine?aeaeaiue (Plachot, 1988). I?e aea/aii? oa?aeoa?enoee iioeeo?a a caeaaeiino? a?ae iieacaiue aei IVF aoei aeyaeaii, ui aeinoia??i? ci?ie a?aeaoaathoueny nei??oa a ii?oiooieoe?iiaeueieo, i?ae oeeoiaaiaoe/ieo oa?aeoa?enoeeao iioeeo?a. Iaeieae/ee ??aaiue aiiiaeueiiai caie?aeiaiiy aoa o iaoe??io?a, i?e/eiith aacie?aeaey o yeeo aoa /ieia?/ee oaeoi?. Oaeei /eiii, o oaeeo iaoe??io?a iaeiaioa ?iia??i?noue caie?aeiaiiy ye ii?iaeueiiai, oae ? aiiiaeueiiai oeio, ine?eueee ??aaiue aiiiaeueiiai caie?aeiaiiy, cie?aia iie?nia?i??, ei?aeth? c ??aiai ii?iaeueiiai caie?aeiaiiy ? ianoaiiy aaa?oiino?. Aeine?aeaeaiiy aieeao ??cieo noai ai?iiiaeueii? noeioeyoe?? ia oa?aeoa?enoeee iioeeo?a Aieea ??cieo noai ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe?? ia oa?aeoa?enoeee iioeeo?a ii/aa ?aoaeueii aeine?aeaeoaaoenue a ca’yceo c aeei?enoaiiyi Ai?Aa. Aeinoia??ia ca?eueoaiiy ??aiy caie?aeiaiiy iioeeo?a aoei iieacaii aeey yeoeaee?oei, io?eiaieo ca aeiiiiiaith Ai?Aa, oiae? ye ??cieoey i?ae ye?noth io?eiaieo aia??ii?a ia i?inoaaeoaaeany (De Sutter et al, 1991). ??aaiue aiaoiei?ae?? aoa aeuei a iioeeoao, ui aoee io?eiai? i?ney noeioeyoe?? Ai?Aa (Plachot, 1988). Iaoa aeine?aeaeaiiy iieacaei aeinoia??i? a?aei?iiino? a ii?oiooieoe?iiaeueieo oa?aeoa?enoeeao iacaie?aeiaieo iioeeo?a (a?aenioeo iaaeic??eeo iioeeo?a; iioeeo?a, ye? aeaaaia?oaaee; yeoeaee?oei, ui caeeoeeeny iacaie?aeiaieie) i?e aeei?enoaii? ??cieo noai ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe??. A oie aea /an eeoa ??aaiue caie?aeiaiiy iioeeo?a aoa aeinoia??ii aeuei i?e aeei?enoaii? Ai?Aa (54,32,2% o a?oi? Ai?Aa+ oa 54,21,5% a a?oi? Ai?Aa+const. noaia, i?ioe 30,43,4% a a?oi? Ai?Aa-, p<0,05), an? ?io? ci?ie a?aeaoaaeeny ye i?ae noaiaie c aeei?enoaiiyi Ai?Aa oa aac ieo, oae ? i?ae ??cieie noaiaie c aeei?enoaiiyi Ai?Aa. Aiaeia?/i? aeniiaee iiaeia aoei c?iaeoe ? aeoiaey/e ?c aeaieo i?i aieea ??cieo noai ai?iiiaeueii? noeioeyoe?? ia ii?oieia?/i? oa?aeoa?enoeee iioeeo?a ieo?. Aeine?aeaeaiiy, ui aoee i?iaaaeai? ia ieoao, aeicaieeee ia o?eueee aea/eoe aieea ??cieo noai ai?iiiaeueii? noeioeyoe?? ia oa?aeoa?enoeee iioeeo?a, aea e aeine?aeeoe aieea ??cieo aeic ai?iii?a, ui aeei?enoiaoaaeeny aeey noeioeyoe?? noia?iaoeyoe??, ia ii?oieia?/i? oa oeeoiaaiaoe/i? ia?aiao?e yeoeaee?oei. Iaoa aeine?aeaeaiiy anoaiiaeei, ui aeei?enoaiiy ??cieo aeic aiiaaeio?ii?i?a a?eueoa iicia/a?oueny ia ii?oieia?/ieo oa oeeoiaaiaoe/ieo oa?aeoa?enoeeao io?eiaieo iioeeo?a, i?ae canoinoaaiiy ??cieo noai ai?iiiaeueii? noeioeyoe??. ?nio? iioeiaeueia aeica aiiaaeio?ii?i?a (a iaoiio aeiaaeeo 5 II), aeei?enoaiiy yei? aeicaiey? io?eioaaoe cia/io e?euee?noue iioeeo?a, ii?oieia?/i? oa oeeoiaaiaoe/i? oa?aeoa?enoeee yeeo ia a?ae??ciythoueny a?ae ia?aiao??a yeoeaee?oei, io?eiaieo a i?e?iaeiiio oeeee?. Iiaeaeueoa ca?eueoaiiy aeice i?eaiaeeoue aei iia??oaiiy ii?oieia?/ieo oa oeeoiaaiaoe/ieo oa?aeoa?enoee iioeeo?a. I?e ioe?ioe? aieeao ai?iiiaeueii? noeioeyoe?? ia io?eiai? iioeeoe iiaeia neacaoe, ui aeei?enoaiiy Ai?Aa i?aeaeuo? ??aaiue caie?aeiaiiy iioeeo?a; aaeeaaiiy ??cieo noai ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe?? nooo?ai ia aieeaa? ia ooieoe?iiaeuei? oa?aeoa?enoeee iioeeo?a, i?e/iio ci?ie a ii?oieia?/ieo oa?aeoa?enoeeao, ui aeine?aeaeoaaeeny a iao?e ?iaio?, ia aoee anoaiiaeai?, a c oeeoiaaiaoe/ieo oa?aeoa?enoee ci?ithaaany eeoa a?aenioie yeoeaee?oei c aeaaaia?aoe??th yaea?iiai iaoa??aeo. Aeine?aeaeaiiy, i?iaaaeai? ia iioeeoao ieoae, iieacaee, ui ci?ie aeic aiiaaeioi?ii?i?a a?eueoa, i?ae ??ci? noaie ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe??, aieeaathoue ia ii?oieia?/i? oa oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a. Aeine?aeaeaiiy ii?oieia?/ieo oa oeeoiaaiaoe/ieo oa?aeoa?enoee iioeeo?a ethaeeie c ??ciei ??aiai caie?aeiaiiy Aeine?aeaeaiiy oa?aeoa?enoee yeoeaee?oei a caeaaeiino? a?ae ??aiy ?o caie?aeiaiiy i?iaiaeeeiny eeoa a iaei?e ?iaio? (Ai?iaueaaa e ae?., 1997). Aea, ia aeaeue, a i?e ii??aithany eeoa ??aaiue aiaoiei?ae??. I?iaaaeai? iaie aeine?aeaeaiiy iieacaee, ui ii?oieia?/i? oa?aeoa?enoeee iioeeo?a a cia/i?e i??? iaoiiaeththoue ??aaiue ?o caie?aeiaiiy. Oae, iaeiaioa e?euee?noue iaaeic??eeo iioeeo?a aoea a a?oi? c ??aiai caie?aeiaiiy (?C) 51-75% (6,70,9%, ?<0,05), iaea?eueoa e?euee?noue aeic??eeo iioeeo?a niinoa??aaeany a a?oi? c ?C 76-100% (82,32,2%, p<0,05). A naith /a?ao, ??aaiue caie?aeiaiiy iioeeo?a ei?aeth? c a?aenioeii IEO (6,22,4% a a?oi? c ?C 0-25%, 8,32,6% –c ?C 26-50%, 17,53,7% – c ?C 51-75% oa 34,68,6% a a?oi? c ?C 76-100%), a c ??aiai iie?nia?iiiai caie?aeiaiiy oaea caeiiii??i?noue ia i?inoaaeo?oueny. A oie aea /an a a?oiao ae?iie c aeinoia??ii aeuei ??aiai ianoaiiy aaa?oiino? niinoa??aaany aeuee ??aaiue iie?nia?iiiai caie?aeiaiiy (22,96,1% oa 4,11,8% a?aeiia?aeii a a?oi? c ?C 26-50% ? 21,05,2% oa 3,41,7% a?aeiia?aeii a a?oi? c ?C 51-75%). Oaeei /eiii, iiaeia neacaoe, ui ii?oieia?/i? oa?aeoa?enoeee io?eiaieo iioeeo?a ethaeeie a cia/i?e i??? iaoiiaeththoue ??aaiue ?o caie?aeiaiiy. Oeeoiaaiaoe/i? oa?aeoa?enoeee iacaie?aeiaieo iioeeo?a caeeoathoueny iaci?iieie a a?oiao c ??ciei ??aiai caie?aeiaiiy. Iaeaeuee ??aaiue ianoaiiy aaa?oiino? niinoa??aaany o ae?iie c ??aiai caie?aeiaiiy iioeeo?a 26-75%. Aeniiaee 1. Noeoii?noue iioeeo?a, ui ia caie?aeieeeny i?ae /an IVF i?ioeaaeo?, aaoa?iaaiia ca nai?ie ii?oieia?/ieie iciaeaie oa oeeoiaaiaoe/ieie oa?aeoa?enoeeaie. Ia?aaaaeia a?eueo?noue yeoeaee?oei, ye? ciaoiaeeeeny ia noaae?? I?? iaeico oa i?noeee aaiei?aeiee iaa?? o?iiinii, iaee ii?iaeueio ii?oieia?th. 2. O?iiiniiiee aiae?c iacaie?aeiaieo iioeeo?a ethaeeie, ui ciaoiaeeeeny ia noaae?? I?? iaeico, anoaiiaea, ui 53,0% oeeo ee?oei i?noeee o?iiiniii? aiiiae??, na?aae yeeo iae/ano?oa cono??/aeany aiaoiei?ae?y o?iiinii a?oi E oa G. 3. Ciaioaiiy e?eueeino? iioeeo?a, io?eiaieo a?ae iaei??? ae?iee, oa iia??oaiiy ?o ii?oieia?/ieo oa?aeoa?enoee i?ecaiaeeoue aei cieaeaiiy caeaoiino? ?o aei caie?aeiaiiy. Iaea?eueoa e?euee?noue yeoeaee?oei c iciaeaie aeaaaia?aoe?? niinoa??aaeanue a a?oi? iioeeo?a c ??aiai caie?aeiaiiy 0-50%. 4. C?inoaiiy a?eo ae?iee, ii/eiath/e c 26 ?ie?a, iaaaoeaii aieeaa? ia ii?oiooieoe?iiaeuei? oa oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a, io?eiaieo i?ae /an IVF i?ia?ai. 5. O iaoe??io?a c ??cieie oi?iaie aacie?aeaey io?eiai? iioeeoe nooo?ai a?ae??ciythoueny ca nai?ie ii?oiooieoe?iiaeueieie iieacieeaie oa caeaoi?noth aei caie?aeiaiiy. Iaeaeuee ??aaiue caie?aeiaiiy yeoeaee?oei in vitro niinoa??aaany o ae?iie c ?ae?iiaoe/iei aacie?aeaeyi (70,5%), iaeieae/ee – o iaoe??io?a, i?e/eiith aacie?aeaey o yeeo aoa /ieia?/ee oaeoi? (43,3%). 6. ?acoeueoaoe aeine?aeaeaiiy aieeao a?eo oa noai ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe?? ia oa?aeoa?enoeee iioeeo?a ieoae e?i?? NAA ni?aiaaeathoue c aiaeia?/ieie aeaieie a iacaie?aeiaieo iioeeoao ethaeeie: c c?inoaiiyi a?eo niinoa??aaeinue iia??oaiiy ii?oieia?/ieo oa oeeoiaaiaoe/ieo oa?aeoa?enoee iioeeo?a. A oie aea /an ci?ie o noai? ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe?? nooo?ai ia iicia/athoueny ia ii?oieia?/ieo oa oeeoiaaiaoe/ieo oa?aeo?enoeeao iioeeo?a ethaeeie oa ieo?. Nienie iioae?eiaaieo iaoeiaeo ?ia?o, ye? a?aeia?aaeathoue iniiai? iieiaeaiiy aeena?oaoe??. 1. Ai?iiaoia O.A., Noaoaiiae/ A.A., Aa?eeye ?.?.Oeeoiaaiaoe/i? aiiiae?? a iacaie?aeiaieo iioeeoao ethaeeie // Oe?a?inueeee iaaee/iee aeueiaiao.–1998.–?4.–N.9-13. 2. Eiaaeaiei O.A., Eae?ca I.A., Noaoaiiae/ A.A., Aa?eeye ?.?. Aieea ??cieo aeic aiiaaeio?ii?i?a ia e?euee?ni? ii?oieia?/i? oa oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a ieoae e?i?? NAA // Oeeoieiaey e aaiaoeea.–1999.–O.33, ?1.–N.49-53. 3. Eiaaeaiei O.A., Noaoaiiae/ A.A., Aa?eeye ?.?., Aeaoii O.A., Aanaiei I.I., C?i/aiei A.I. Aeine?aeaeaiiy ii?oieia?/ieo oa oeeoiaaiaoe/ieo oa?aeoa?enoee iioeeo?a ethaeeie c ??ciei ??aiai caie?aeiaiiy // A?niee i?iaeai a?ieia?? ? iaaeeoeeie.–1999.–?2.–N.26-29. 4. Eiaaeaiei O.A., Noaoaiiae/ A.A., Aa?eeye ?.?. Aeei?enoaiiy eaai?aoi?ieo oaa?ei aeey aea/aiiy oaeoi??a, ui aieeaathoue ia caie?aeiaiiy in vitro // A?niee i?iaeai a?ieia?? ? iaaeeoeeie.–1999.–?3.–N.6-9. 5. Eiaaeaiei O.A., Noaoaiiae/ A.A., Aa?eeye ?.?., Aeaoii O.A., Aanaiei I.I., C?i/aiei A.I. Aeine?aeaeaiiy aieeao ??cieo noai ai?iiiaeueii? noeioeyoe?? ia oa?aeoa?enoeee iioeeo?a, io?eiaieo i?ae /an IVF i?ioeaaeo? // A?niee i?iaeai a?ieia?? ? iaaeeoeeie.–1999.–?4.–N.22-26. 6. Aa?eeye ?.?., Ai?iiaoia O.A., Noaoaiiae/ A.A., Eae?ca I.A., ?na?aa A.A., Coe?i A.Ae., C?i/aiei A.I. Ii?oieia?/i? oa oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a ae?iie ??cieo a?eiaeo a?oi // I?iaeaie aeieia?/ii? oa iaaee/ii? aaiaoeee ? ee?i?/ii? ?ioiieia??.– Ee?a - Eoaainuee: AAO “EIAe”,–1998.–N.211-213. 7. Ai?iiaoiay O.A., Noaoaiiae/ A.A., Cei/aiei A.I. Oeeoiaaiaoe/aneee e ii?oieiae/aneee aiaeec iaiieiaeioai?eaoeony iioeeoia /aeiaaea // Aanieiaeea: aniiiiaaoaeueiua ?ai?iaeoeoeaiua oaoiieiaee; Nai?iee iao/iuo o?oaeia neiiiceoia n iaaeaeoia?iaeiui o/anoeai.–Eeaa.–1997.– N.142. 8. Goropashnaya T., Lakiza O.V., Stefanovich A., Barilyak I. The effect of different doses of gonadotropins on number, quality and cytogenetics of mouse oocytes // J. of Assisted Reproduction and Genetics.–1999.–V.16,?3.–P.156. 9. Kovalenko T.A., Stefanovich A.V., Barilyak I.R., Dakhno F.V., Sirenko V.Y., Gasenko E.A., Zinchenko V.M. Effects of hormonal stimulation on parameters of human oocytes // J. of Assisted Reproduction and Genetics.–1999.–V.16,?3.–P.157. Eiaaeaiei O.A. Oeeoiaaiaoe/ia oa ii?oiooieoe?iiaeueia oa?aeoa?enoeea iioeeo?a ethaeeie o ca’yceo c ?o caie?aeiaiiyi in vitro (ee?i?ei-aenia?eiaioaeueia aeine?aeaeaiiy). ?oeiien aeena?oaoe?? ia caeiaoooy a/aiiai nooiaiy eaiaeeaeaoa a?ieia?/ieo iaoe ii niaoe?aeueiino? 03.00.15 – aaiaoeea (a?ieia?/i? iaoee). Oe?a?inueeee iaoeiaee a?a??i?/iee oeaio?. Ee?a, 1999. Anoaiiaeaii, ui iioeeoe ii?iaeueii? ii?oieia?? ia?aaaaeii ciaoiaeyoueny ia noaae?? I?? iaeico oa iathoue a?eueoo ?iia??i?noue caie?aeiaiiy, ye ii?iaeueiiai, oae ? aiiiaeueiiai. O?iiiniiiee aiae?c iioeeo?a ethaeeie, ye? caeeoeeeny iacaie?aeiaieie i?ney IVF oa ciaoiaeeeeny ia noaae?? I?? iaeico, anoaiiaea, ui 53,0% oeeo ee?oei i?noeee o?iiiniii? aiiiae??. E??i oiai, aoei iieacaii, ui iia??oaiiy e?euee?nieo oa ii?oieia?/ieo oa?aeoa?enoee io?eiaieo iioeeo?a i?ecaiaeeoue aei cieaeaiiy ??aiy ?o caie?aeiaiiy. Ca?eueoaiiy a?eo ae?iee iaaaoeaii aieeaa? ia ii?oiooieoe?iiaeuei? oa oeeoiaaiaoe/i? oa?aeoa?enoeee iioeeo?a, io?eiaieo i?ae /an IVF i?ia?ai. O iaoe??io?a c ??cieie oi?iaie aacie?aeaey io?eiai? iioeeoe nooo?ai a?ae??ciythoueny ca nai?ie ii?oiooieoe?iiaeueieie iieacieeaie oa caeaoi?noth aei caie?aeiaiiy. ?acoeueoaoe aeine?aeaeaiiy aieeao a?eo oa noai ai?iiiaeueii? noeioeyoe?? noia?iaoeyoe?? ia oa?aeoa?enoeee iioeeo?a ieoae e?i?? NAA ni?aiaaeathoue c aiaeia?/ieie aeaieie i?i iacaie?aeiai? iioeeoe ethaeeie. C oaie aeena?oaoe?? iioae?eiaaii 9 iaoeiaeo ?ia?o. Eeth/ia? neiaa: iacaie?aeiai? iioeeoe, oeeoiaaiaoe/i? oa?aeoa?enoeee, ii?oieia?/i? oa?aeoa?enoeee iioeeo?a, iaoaoaca ?? iaeico, ai?iiiaeueia noeioeyoe?y, a?e ae?iee, caie?aeiaiiy in vitro. Eiaaeaiei O.A. Oeeoiaaiaoe/aneaey e ii?oiooieoeeiiaeueiay oa?aeoa?enoeea iioeeoia /aeiaaea a nayce n eo iieiaeioai?aieai ?n vitro (eeeieei-yenia?eiaioaeueiia enneaaeiaaiea). ?oeiienue aeenna?oaoeee ia nieneaiea o/aiie noaiaie eaiaeeaeaoa aeieiae/aneeo iaoe ii niaoeeaeueiinoe 03.00.15 – aaiaoeea (aeieiae/aneea iaoee). Oe?aeineee iao/iue aeaeaie/aneee oeaio?. Eeaa, 1999. Iaoiae iieiaeioai?aiey in vitro (in vitro fertilization, IVF) oe?iei aiaae?yaony a iaaeeoeeineoth i?aeoeeo aieueoeinoaa no?ai ie?a, eae iaoiae ea/aiey iiiaeo oi?i aanieiaeey, ia iiaeaeathueony ea/aieth ae?oaeie iaoiaeaie. Niaeo? aai i?eiaiaiey iinoiyiii ?anoe?yaony, aeeth/ay naiua oyaeaeua oi?iu aanieiaeey, a /anoiinoe ioaeneiai. Nooue iaoiaea caeeth/aaony a iieo/aiee c?aeuo iioeeoia /aeiaaea iinea ai?iiiaeueiie noeioeyoeee noia?iaoeyoeee, iieiaeioai?aiee eo aia i?aaiecia e ia?aiina iieo/aiiuo yia?eiiia a iaoeo aeaiueiu, aaea i?ienoiaeeo eo eiieaioaoeey e aeaeueiaeoaa ?acaeoea. Aai i?eiaiaiea a Oe?aeia iniaaiii aeooaeueii, iineieueeo aeaiia?aoe/aneay e yieaeaieieiae/aneay neooaoeey a iineaaeiea aiaeu oa?aeoa?ecoaony aeaiiioeyoeeae e aunieei o?iaiai aanieiaeey (ieiei 20% noi?oaeaneeo ia?). Eniieueciaaiea iiauo ?ai?iaeooeeaiuo oaoiieiaee e iaoiaea IVF a /anoiinoe iicaieyao ?aoaoue cia/eoaeueiia eiee/anoai i?iaeai, naycaiiuo eae n aeaineei, oae e n ioaeneei aanieiaeeai. Eiaiii iiaua ?ai?iaeoeoeaiua oaoiieiaee iiaoo noaoue iaeiei ec aeaenoaaiiuo n?aaenoa nio?aiaiey aaiioiiaea Oe?aeiu a oneiaeyo yeieiae/aneiai e?ecena, oneeaiiiai *a?iiaueueneie eaoano?ioie. A ianoiyuaa a?aiy a Oe?aeia nicaeaio 7 eaai?aoi?ee, eioi?ua eniieuecotho iaoiae IVF aeey ea/aiey ?aciuo oi?i aanieiaeey. Ianiio?y ia oi, /oi ioa/anoaaiiuie o/aiuie e eeeieoeenoaie o/eouaaaony iiuo aaaeoueo eaai?aoi?ee ie?a, yooaeoeaiinoue iaoiaea aei neo ii? inoaaony aeinoaoi/ii ieceie. I?aaeiieaaaaony, /oi iaoaea/e ea/aiey aanieiaeey iaoiaeii IVF iaoneiaeaiu ii?aaeaeaiiuie ii?oiooieoeeiiaeueiuie oa?aeoa?enoeeaie iioeeoia e o?iiiniiiuie aiiiaeeyie, eioi?ua aicieeatho ai a?aiy aaiaoiaaiaca, iieiaeioai?aiey e ?aiiaai yia?eiiaeueiiai ?acaeoey. E?iia oiai, ?yae aeieiae/aneeo e eeeie/aneeo oaeoi?ia, a ia?aoth i/a?aaeue oaeeo eae, aic?ano aeaiueiu, iieacaiey e IVF e ai?iaiaeueiay noeioeyoeey noia?iaoeyoeee iiaoo iaaaoeaii aeeyoue ia eiee/anoaaiiua, ii?oiooieoeeiiaeueiua e oeeoiaaiaoe/aneea oa?aeoa?enoeee iieo/aiiuo iioeeoia, e, oaeei ia?acii, ia yooaeoeaiinoue iieiaeioai?aiey in vitro. Oeaeueth ?aaiou auei enneaaeiaaiea ii?oiooieoeeiiaeueiuo e oeeoiaaiaoe/aneeo oa?aeoa?enoee iioeeoia /aeiaaea e aeeyiey ia ieo iaeioi?uo eeeie/aneeo e aeieiae/aneeo oaeoi?ia (aic?anoa aeaiueiu, ai?iiiaeueiie noeioeyoeee e iieacaiee e IVF). Auei enneaaeiaaii 492 iaiieiaeioai?eaoeony iioeeoa, iieo/aiiuo io 214 aeaiuei, i?ioiaeeaoeo eo?n ea/aiey aanieiaeey iaoiaeii IVF a eeeieeao a. Eeaaa. Aeey oiai, /oiau ii?aaeaeeoue, iiaeii ee yeno?aiiee?iaaoue caeiiiia?iinoe, onoaiiaeaiiua i?e enneaaeiaaiee iaiieiaeioai?eaoeony iioeeoia, ia anth niaieoiiinoue yeoeaeeaoie, iieo/aiiuo a oiaea IVF i?ia?aii, auei i?iaaaeaii aeiiieieoaeueiia enneaaeiaaiea ia 988 iioeeoao iuoae eeiee NAA. A ?acoeueoaoa i?iaaaeaiiiai enneaaeiaaiey auei onoaiiaeaii, /oi iioeeou n ii?iaeueiie ii?oieiaeae a iniiaiii iaoiaeyony ia noaaeee I?? iaeica e eiatho aieueooth aa?iyoiinoue iieiaeioai?aiey eae ii?iaeueiiai, oae e aiiiaeueiiai. O?iiiniiiue aiaeec iioeeoia /aeiaaea, eioi?ua inoaeenue iaiieiaeioai?aiiuie iinea IVF e iaoiaeeeenue ia noaaeee I?? iaeica, iieacae, /oi 53,0% ec ieo ianee o?iiiniiiua aiiiaeee. E?iia oiai, auei onoaiiaeaii, /oi oooaeoaiea eiee/anoaaiiuo e ii?oieiae/aneeo oa?aeoa?enoee iieo/aiiuo iioeeoia i?eaiaeeo e nieaeaieth o?iaiy eo iieiaeioai?aiey. Oaaee/aiea aic?anoa aeaiueiu iaaaoeaii aeeyao ia ii?oiooieoeeiiaeueiua e oeeoiaaiaoe/aneea oa?aeoa?enoeee iioeeoia, iieo/aiiuo i?e i?iaaaeaiee IVF i?ia?aii. O iaoeeaioia n ?aciuie oi?iaie aanieiaeey iieo/aiiua iioeeou cia/eoaeueii ioee/athony ii naiei ii?oiooieoeeiiaeueiui iieacaoaeyi e ii niiniaiinoe e iieiaeioai?aieth. ?acoeueoaou enneaaeiaaiey aeeyiey aic?anoa e noai ai?iiiaeueiie noeioeyoeee noia?iaoeyoeee ia oa?aeoa?enoeee iioeeoia iuoae eeiee NAA niaiaaeatho n aiaeiae/iuie aeaiiuie i iaiieiaeioai?eaoeony iioeeoao /aeiaaea. Ii oaia aeenna?oaoeee auei iioaeeeiaaii 9 iao/iuo ?aaio. Eeth/aaua neiaa: iaiieiaeioai?eaoeany iioeeou, oeeoiaaiaoe/aneea oa?aeoa?enoeee, ii?oieiae/aneea oa?aeoa?enoeee iioeeoia, ai?iiiaeueiay noeioeyoeey, iaoaoaca ?? iaeica, aic?ano aeaiueiu, iieiaeioai?aiea in vitro. Kovalenko T.A. Cytogenetical and morphological oocytes charanteristics associated with in vitro fertilization (nlinins and eoperimental investigation). The manuscript of dissertation for a Candidate’s degree in Biology, Speciality 03.00.15–genetics (biological science). Ukrainian Scientific Centre of Hygiene. Ko?v, 1999. Correlation between oocytes with normal morphology and Metaphase II stage, level of fertilization (bofh normal and abnormal) was estimated. The level of chromosome anomalies in oocytes of second meiotic metaphase comprised 53,0%. The decreasing of number and aggravation of morphological oocyte parameters corelates with decreasing of their fertilization rate. Decreasing of woman age influences on morphological and cytogenetics oocyte parameters in negative way. In groups of patients with different causes of infertility recovering oocytes distinguish by their morphological, functional parameters and fertilization potential. Results of age and different schemes of gormonal stimulation influence on unfertilized human oocyte parameters and oocytes from CBA mice where compared. 9 scientific papers within the context of dissertation had been published. Key words: unfertilized oocytes, cytogenetical parametres, morphological oocytes characteristics, meiotic II metaphase, hormonal stimulation, women’s age, in vitro fertilization.

Похожие записи